Cue Biopharma: Dual Antibody Approach Targets Growth Market for Allergies - B. Riley Sees Over 100% Upside Potential
Reading Time: 3 minutes
Strategic focus on functional therapies for autoimmune and allergic diseases. B. Riley initiates coverage with a buy recommendation and a price target of $83. Lead candidate CUE-221 demonstrates four to eight times the potency in IgE neutralization compared to Xolair. Strategic focus on immunological solutions Cue Biopharma (CUE) is a clinical-stage biopharmaceutical company focused on developing targeted treatment approaches for allergic and autoimmune diseases. At the core of the company’s strategy is the proprietary Immuno-STAT platform,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
